chronic severe disabling pain
Pain · 2005–2010
4decisions
3medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxycodone hydrochloride and naloxone hydrochloride dihydrate chronic severe disabling pain not responding to non-narcotic analgesics | Jul 2010 | Not recommended | no section in document |
| oxycodone hydrochloride and naloxone hydrochloride dihydrate Chronic severe disabling pain not responding to non-narcotic analgesics. | Jul 2010 | Not recommended | no section in document |
| hydromorphone hydrochloride Chronic severe disabling pain not responding to non-narcotic analgesics. The submission also requested listing in the Palliative Care Schedule for palliative… | Nov 2008 | Recommended with restriction | no section in document |
| buprenorphine Chronic severe disabling pain not responding to non-narcotic analgesics. The transdermal patch formulation is intended to treat patients with chronic severe… | Jul 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.